Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03588039 · ClinicalTrials.gov registry record · Phase 1
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Athenex.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03588039: Clinical Trial Phase 1 study, sponsored by Athenex.
NCT03588039 is a Phase 1 study that was terminated before completion, run by Athenex. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03588039, a Phase 1 study, was terminated before completion, sponsored by Athenex.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is an open-label, Phase 1 dose-escalation study followed by a 2-arm expansion cohort of Oraxol administered in combination with pembrolizumab.
Primary Outcome
dose limiting toxicities occuring in the first cycle of therapy
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Oraxol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2018-10-25 |
| Est. Completion | 2023-05-12 |
| Phase | Phase 1 |
Why NCT03588039 stopped before completion
NCT03588039 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03588039 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03588039 about?
NCT03588039 is a clinical study titled "Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors". This is an open-label, Phase 1 dose-escalation study followed by a 2-arm expansion cohort of Oraxol administered in combination with pembrolizumab.
What is the current status of trial NCT03588039?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2018-10-25. Estimated completion is 2023-05-12.
What interventions are being tested in trial NCT03588039?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Oraxol (DRUG).
Who is sponsoring clinical trial NCT03588039?
This trial is sponsored by Athenex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03588039's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI